Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
DYN · Why this verdict
Why Dyne Therapeutics (DYN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Dyne Therapeutics is a pre-commercial biotechnology company in a technical breakout with analyst targets implying more than 80% upside — reflecting pipeline conviction — yet the business burns cash with no moat, carries 18% short interest, and an extreme put/call ratio, making the investment case almost entirely dependent on clinical progress rather than financial fundamentals.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus targets imply more than 80% upside from current levels — with the consensus price target near $34 versus a current price near $19 — reflecting strong conviction in the clinical pipeline and a risk/reward ratio that is highly favorable on a probability-weighted basis if even a subset of pipeline outcomes are positive. Sentiment breakdown | The stock moves toward the consensus analyst target within 12 months following positive clinical data or regulatory milestones. | ↓Deteriorating |
| CounterAnalyst targets in pre-commercial biotechnology are highly sensitive to trial outcome assumptions; if key clinical milestones are delayed or miss primary endpoints, consensus targets would reset materially lower and the implied upside would evaporate. | ||
A confirmed golden cross, price above all major moving averages, a bullish MACD, and rising on-balance volume collectively signal a technical breakout with institutional buying pressure supporting the current price level. Momentum breakdown | The stock sustains above its 200-day moving average for the next 6 months as price momentum and volume accumulation persist. | ↑Improving |
| CounterTechnical breakouts in cash-burning, pre-commercial biotechnology companies are particularly susceptible to reversal on clinical setbacks — a single negative data readout could erase multiple months of technical progress in a single session. | ||
The company generates no operating cash flow, carries no competitive moat, and has negative free cash flow — operating below the minimum quality threshold for an investable business and dependent on capital markets or clinical milestones to fund continued operations. Quality breakdown | The company demonstrates a clear path to positive free cash flow through a disclosed funding runway extension or a commercial milestone within the next four quarters. | →Stable |
| CounterThree consecutive quarters of losses beating estimates — most recently by 6.65% — suggest cash burn is being managed tighter than projected; if the company continues to outperform its own spending trajectory, the runway may extend materially and the quality concern becomes less pressing near term. | ||
Short interest of 18% and a put/call ratio of 11.50 — among the most extreme hedging combinations in the market — indicate intense institutional skepticism and binary event positioning that creates outsized downside risk if clinical news disappoints. Risk breakdown | Short interest falls below 10% and the put/call ratio falls below 3.0 within six months as positioning normalizes following a positive clinical catalyst. | ↑Improving |
| CounterExtreme short interest and put/call readings at these levels can fuel a violent short squeeze on any positive announcement; the 18% short interest itself represents a large pool of forced buyers if sentiment shifts even modestly. | ||
Analyst consensus targets imply more than 80% upside from current levels — with the consensus price target near $34 versus a current price near $19 — reflecting strong conviction in the clinical pipeline and a risk/reward ratio that is highly favorable on a probability-weighted basis if even a subset of pipeline outcomes are positive.
↓DeterioratingSentiment breakdown
- Expectation
- The stock moves toward the consensus analyst target within 12 months following positive clinical data or regulatory milestones.
CounterAnalyst targets in pre-commercial biotechnology are highly sensitive to trial outcome assumptions; if key clinical milestones are delayed or miss primary endpoints, consensus targets would reset materially lower and the implied upside would evaporate.
A confirmed golden cross, price above all major moving averages, a bullish MACD, and rising on-balance volume collectively signal a technical breakout with institutional buying pressure supporting the current price level.
↑ImprovingMomentum breakdown
- Expectation
- The stock sustains above its 200-day moving average for the next 6 months as price momentum and volume accumulation persist.
CounterTechnical breakouts in cash-burning, pre-commercial biotechnology companies are particularly susceptible to reversal on clinical setbacks — a single negative data readout could erase multiple months of technical progress in a single session.
The company generates no operating cash flow, carries no competitive moat, and has negative free cash flow — operating below the minimum quality threshold for an investable business and dependent on capital markets or clinical milestones to fund continued operations.
→StableQuality breakdown
- Expectation
- The company demonstrates a clear path to positive free cash flow through a disclosed funding runway extension or a commercial milestone within the next four quarters.
CounterThree consecutive quarters of losses beating estimates — most recently by 6.65% — suggest cash burn is being managed tighter than projected; if the company continues to outperform its own spending trajectory, the runway may extend materially and the quality concern becomes less pressing near term.
Short interest of 18% and a put/call ratio of 11.50 — among the most extreme hedging combinations in the market — indicate intense institutional skepticism and binary event positioning that creates outsized downside risk if clinical news disappoints.
↑ImprovingRisk breakdown
- Expectation
- Short interest falls below 10% and the put/call ratio falls below 3.0 within six months as positioning normalizes following a positive clinical catalyst.
CounterExtreme short interest and put/call readings at these levels can fuel a violent short squeeze on any positive announcement; the 18% short interest itself represents a large pool of forced buyers if sentiment shifts even modestly.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 1.4 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -2.6%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 2.5 |
| Analyst rating | 8.6 |
| Price target | 10.0 |
- ▸LLM news sentiment: -0.50 (n=2)
- ▸Analyst upside: 102%
Insider
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.4 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $65,617,759 (2.069% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.6 |
| growth rank | 5.0 |
Technical
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 1.0 |
| 52w position | 2.4 |
| gap | 7.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 2.3 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 6.5 |
| debt equity | 8.7 |
| news risk | 5.5 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 6.17
- ▸High IV: 92%
Catalyst
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 7 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:5.5>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- INSIDER:2.07%=EXTREME
- EARNINGS_PROXIMITY:7d<=7d
Warning (1)
- DEATH_CROSS:momentum=6.0>=5.0 recovering
Reward-to-Risk
5.47
Upside
+82.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 54
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the INSIDER gate's 2.07%=EXTREME outcome against Value at 9.0 and asymmetric R:R of 5.47.
The strongest dimensions are Value at 9.0, Sentiment at 7.1, and Momentum at 6.0; the weakest are Quality at 1.5, Technical at 2.7, and Risk (lower is worse) at 3.1. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 5.47 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Technical Breakout Momentum
Trip ifStock falls below its 200-day moving average for 3 consecutive weeks.
- P2Pre Commercial Cash Burn
Trip ifFree cash flow rises above $0 for 2 consecutive quarters.
- P3Extreme Short And Options Skew
Trip ifShort interest falls below 10% and put/call ratio falls below 3.0 for 2 consecutive measurement periods.
- P4Analyst Implied Pipeline Upside
Trip ifAnalyst consensus price target falls below $25, representing less than 33% upside from the current price near $19.